| ￥3000 | |
| Z05569-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 25.4 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 35-42 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of LAYN, His, Human is greater than 95% as determined by SEC-HPLC »
LAYN, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Layilin (LAYN) is a critical gene that regulates T cell function. LAYN is correlated with prognosis and immune infiltrating levels of, including those of CD8 T cells, CD4 T cells, macrophages, neutrophils, and DCs in multiple cancers, especially in colon and gastric cancer patients. In addition, LAYN expression potentially contributes to regulation of tumor-associated macrophages (TAMs), DCs, T cell exhaustion and Tregs in colon and gastric cancer. |
| Synonyms | Layilin; FLJ30977; FLJ31092; LAYN; LYAN |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
